Journal
ONCOTARGET
Volume 8, Issue 9, Pages 14416-14427Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.14796
Keywords
checkpoint inhibitor; PD-L1; human papillomavirus; oropharyngeal squamous cell carcinomas; tumour infiltrating lymphocytes
Categories
Funding
- Cancer Research UK [C480/A15578, C5759/A12328]
Ask authors/readers for more resources
Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e. g. PD-1/PD-L1) and co-stimulatory pathways (e. g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/ PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8(+) T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available